WO2002033120B1 - Non-invasive prenatal monitoring - Google Patents

Non-invasive prenatal monitoring

Info

Publication number
WO2002033120B1
WO2002033120B1 PCT/GB2001/004629 GB0104629W WO0233120B1 WO 2002033120 B1 WO2002033120 B1 WO 2002033120B1 GB 0104629 W GB0104629 W GB 0104629W WO 0233120 B1 WO0233120 B1 WO 0233120B1
Authority
WO
WIPO (PCT)
Prior art keywords
rna
fetal
maternal
sample
detecting
Prior art date
Application number
PCT/GB2001/004629
Other languages
French (fr)
Other versions
WO2002033120A2 (en
WO2002033120A3 (en
Inventor
Yuk Ming Dennis Lo
Lit Man Poon
Original Assignee
Univ Hong Kong Chinese
Yuk Ming Dennis Lo
Lit Man Poon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Chinese, Yuk Ming Dennis Lo, Lit Man Poon filed Critical Univ Hong Kong Chinese
Priority to AU2001295738A priority Critical patent/AU2001295738A1/en
Publication of WO2002033120A2 publication Critical patent/WO2002033120A2/en
Publication of WO2002033120A3 publication Critical patent/WO2002033120A3/en
Publication of WO2002033120B1 publication Critical patent/WO2002033120B1/en
Priority to HK04101313A priority patent/HK1058529A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Embodiments of the present invention are directed to the detection of fetal or maternal RNA in a blood sample from a pregnant subject, and may involve subjecting the sample to a test for fetal or maternal analysis indicative of a fetal or maternal condition or characteristics. For instance, the RNA analysis may involve the assessment of the gene expression pattern of an unborn fetus by analysing a blood sample from the mother. The prenatal monitoring technology allows, for the first time, the detection of genes which are expressed by the fetus, just by analysis of a sample of maternal blood. In specific embodiments, the prenatal monitoring technology is based on the discovery of circulating RNA of fetal origin in the plasma of pregnant women. In general, the detection method performed on a maternal serum or plasma sample from a pregnant female comprises detecting the presence of RNA of fetal or maternal original in the sample.

Claims

AMENDED CLAIMS[received by the International Bureau on 14 October 2002 (14.10.02); original claims 1-27 replaced by amended claims 1-26 (4 pages)]
1. A method of performing prenatal monitoring or testing of a blood sample obtained from a pregnant subject, the method comprising: removing all or substantially all nucleated and anucleated cell populations from the blood sample to obtain a remaining material; amplifying a nucleic acid from the remaining material and subjecting the nucleic acid to a test for fetal or maternal RNA analysis indicative of a fetal or maternal condition or characteristic resulting from the pregnancy of the pregnant subject.
2. The method according to claim 1 wherein all nucleated and anucleated cell populations are removed from the blood sample to obtain the remaining material.
3. The method according to claim 1 wherein the remaining material comprises non-cellular matter, and wherein the RNA analysis is performed on the non- cellular matter of the remaining material.
4. The method according to claim 1 wherein the remaining material comprises cellular matter, and wherein the RNA analysis is performed on the cellular matter of the remaining material.
5. The method according to claim 1 wherein the remaining material comprises plasma.
6. The method according to claim 1 wherein the remaining material comprises serum.
7. A detection method performed on a maternal serum or plasma sample from a pregnant female, the method comprising: amplifying a nucleic acid from the maternal serum or plasma sample; and detecting the presence of RNA of fetal origin in the sample.
8. The method according to claim 7 further comprising amplifying the fetal RNA to facilitate detecting the presence of RNA of fetal origin in the sample.
9. The method according to claim 8 wherein the fetal RNA is converted into complementary DNA by a reverse transcriptase and then detected by a polymerase chain reaction.
10. The method according to claim 8 or claim 9 wherein at least one fetal sequence specific oligonucleotide is used in amplifying the fetal RNA.
11. The method according to claim any one of claims 7 to 10 wherein the fetal RNA is detected using a sequence specific probe.
12. The method according to claim any one of claims 7 to 11 wherein detecting the presence of RNA of fetal origin in the sample comprises detecting the presence of a fetal RNA transcribed from the Y chromosome.
13. The method according to claim 12 wherein the fetal RNA is transcribed from the ZFY gene.
14. The method according to claim 12 or claim 13 further comprising determining the sex of the fetus from the RNA of fetal origin in the sample.
15. The method according to claim any one of claims 7 to 11 wherein detecting the presence of RNA of fetal origin in the sample comprises detecting the presence of a fetal RNA transcribed from a gene or other DNA sequences inherited from the father or the mother.
16. The method according to claim any one of claims 7 to 11 wherein the RNA is detected by any one of a physical method, an immunological method, and a biochemical method.
17. A detection method performed on a maternal serum or plasma sample from a pregnant female, the method comprising: amplifying a nucleic acid from the maternal serum or plasma sample; and detecting the presence of RNA of fetal or maternal origin in the sample.
18. The method according to claim 17 further comprising amplifying the fetal or maternal RNA to facilitate detecting the presence of RNA of fetal or maternal origin in the sample.
13
19. The method according to claim 18 wherein the fetal or maternal RNA is converted into complementary DNA by reverse transcriptase and then detected by a polymerase chain reaction.
20. The method according to claim 18 or claim 19 wherein at least one fetal or maternal sequence specific oligonucleotide is used in amplifying the fetal or maternal RNA resulting from the pregnancy of the pregnant female.
21. The method according to claim any one of claims 17 to 20 wherein the fetal or maternal RNA is detected using a sequence specific probe.
22. The method according to claim any one of claims 17 to 21 wherein detecting the presence of RNA of fetal or maternal origin in the sample comprises detecting the presence of RNA transcribed from genes on chromosome 6.
23. The method according to claim 22 wherein the RNA is transcribed from the HLA-G gene.
24. A method of performing prenatal monitoring or testing, the method comprising the steps of:
(i) providing a maternal blood sample;
(ii) separating the sample into a predominantly cellular fraction (fraction 1) and a predominantly non-cellular fraction (fraction 2);
(iii) detecting the presence of RNA of fetal origin in fraction 2;
(iv) providing a diagnosis based on at least one of the presence, quantity, concentration, sequence, and biochemical composition of the detected RNA.
25. The method according to claim 24 further comprising the step of allowing clotting in the maternal blood sample to obtain a serum and using the serum for steps (iii) and (iv).
14
26. A method of performing a prenatal monitoring or testing on a maternal blood sample of a pregnant subject, the method comprising: obtaining a non-cellular fraction of the maternal blood sample; amplifying a nucleic acid from the non-cellular fraction; and performing an RNA analysis on the nucleic acid for expressed human genes of fetal or maternal origin resulting from the pregnancy of the pregnant subject.
15
PCT/GB2001/004629 2000-10-17 2001-10-17 Non-invasive prenatal monitoring WO2002033120A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001295738A AU2001295738A1 (en) 2000-10-17 2001-10-17 Non-invasive prenatal monitoring
HK04101313A HK1058529A1 (en) 2000-10-17 2004-02-24 Non-invasive prenatal monitoring.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24141700P 2000-10-17 2000-10-17
US60/241,417 2000-10-17
US09/876,005 2001-06-06
US09/876,005 US6664056B2 (en) 2000-10-17 2001-06-06 Non-invasive prenatal monitoring

Publications (3)

Publication Number Publication Date
WO2002033120A2 WO2002033120A2 (en) 2002-04-25
WO2002033120A3 WO2002033120A3 (en) 2002-12-27
WO2002033120B1 true WO2002033120B1 (en) 2003-02-20

Family

ID=26934284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004629 WO2002033120A2 (en) 2000-10-17 2001-10-17 Non-invasive prenatal monitoring

Country Status (5)

Country Link
US (1) US6664056B2 (en)
CN (1) CN1219074C (en)
AU (1) AU2001295738A1 (en)
HK (1) HK1058529A1 (en)
WO (1) WO2002033120A2 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051341A1 (en) * 1997-03-04 2001-12-13 Isis Innovation Limited Non-invasive prenatal diagnosis
US7767422B2 (en) * 1998-09-22 2010-08-03 Oncomedx, Inc. Detection of 5T4 RNA in plasma and serum
EP1354060B1 (en) * 2000-08-28 2011-02-09 Oncomedx, Inc. 5t4 rna in plasma and serum as a marker for neoplastic disease
JP2006523082A (en) * 2002-03-01 2006-10-12 ラブジェン， インコーポレイテッド Rapid analysis of mutations in the genome
US6977162B2 (en) * 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
US7727720B2 (en) * 2002-05-08 2010-06-01 Ravgen, Inc. Methods for detection of genetic disorders
US20070178478A1 (en) * 2002-05-08 2007-08-02 Dhallan Ravinder S Methods for detection of genetic disorders
US7442506B2 (en) * 2002-05-08 2008-10-28 Ravgen, Inc. Methods for detection of genetic disorders
US20040009518A1 (en) * 2002-05-14 2004-01-15 The Chinese University Of Hong Kong Methods for evaluating a disease condition by nucleic acid detection and fractionation
CA2445204C (en) 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
CA2513292C (en) 2003-01-17 2016-04-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
WO2005021793A1 (en) * 2003-08-29 2005-03-10 Pantarhei Bioscience B.V. Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood
WO2005072133A2 (en) * 2004-01-27 2005-08-11 Zoragen, Inc. Nucleic acid detection
US20100216151A1 (en) * 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US20100216153A1 (en) * 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
CN102010902B (en) * 2005-03-18 2012-05-23 香港中文大学 Markers for prenatal diagnosis and monitoring
PT2385143T (en) 2006-02-02 2016-10-18 Univ Leland Stanford Junior Non-invasive fetal genetic screening by digital analysis
CA2645045A1 (en) * 2006-03-06 2007-09-13 The Trustees Of Columbia University In The City Of New York Specific amplification of fetal dna sequences from a mixed, fetal-maternal source
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc Use of highly parallel snp genotyping for fetal diagnosis
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
TWI335354B (en) * 2006-09-27 2011-01-01 Univ Hong Kong Chinese Methods for the detection of the degree of the methylation of a target dna and kits
EP3067807A1 (en) 2007-07-23 2016-09-14 The Chinese University of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
US20100112590A1 (en) * 2007-07-23 2010-05-06 The Chinese University Of Hong Kong Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment
WO2009092068A1 (en) 2008-01-18 2009-07-23 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US8709726B2 (en) 2008-03-11 2014-04-29 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
EP2952589B1 (en) * 2008-09-20 2018-02-14 The Board of Trustees of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DK3290530T3 (en) 2009-02-18 2020-12-07 Streck Inc PRESERVATION OF CELL-FREE NUCLEIC ACIDS
AU2010239131A1 (en) 2009-04-21 2011-11-17 Genetic Technologies Limited Methods for obtaining fetal genetic material
US20110070590A1 (en) 2009-09-22 2011-03-24 Jan Rohozinski Primers and Methods for Determining RhD Zygosity
AU2010315037B9 (en) 2009-11-05 2015-04-23 Sequenom, Inc. Fetal genomic analysis from a maternal biological sample
EA034241B1 (en) * 2009-11-06 2020-01-21 Те Чайниз Юниверсити Ов Гонконг Method for performing prenatal diagnosis of a sequence imbalance
EP2516680B1 (en) 2009-12-22 2016-04-06 Sequenom, Inc. Processes and kits for identifying aneuploidy
AU2010336017B2 (en) 2009-12-23 2016-04-28 Genetic Technologies Limited Methods of enriching and detecting fetal nucleic acids
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
WO2012012725A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US10533223B2 (en) 2010-08-06 2020-01-14 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US11031095B2 (en) 2010-08-06 2021-06-08 Ariosa Diagnostics, Inc. Assay systems for determination of fetal copy number variation
US20130261003A1 (en) 2010-08-06 2013-10-03 Ariosa Diagnostics, In. Ligation-based detection of genetic variants
US20130040375A1 (en) 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US20140342940A1 (en) 2011-01-25 2014-11-20 Ariosa Diagnostics, Inc. Detection of Target Nucleic Acids using Hybridization
US10167508B2 (en) 2010-08-06 2019-01-01 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
US11203786B2 (en) 2010-08-06 2021-12-21 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
US11270781B2 (en) 2011-01-25 2022-03-08 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
US9994897B2 (en) 2013-03-08 2018-06-12 Ariosa Diagnostics, Inc. Non-invasive fetal sex determination
US8756020B2 (en) 2011-01-25 2014-06-17 Ariosa Diagnostics, Inc. Enhanced risk probabilities using biomolecule estimations
CN103717750B (en) 2011-04-29 2017-03-08 塞昆纳姆股份有限公司 The quantitation of minority nucleic acid substances
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
WO2012177792A2 (en) 2011-06-24 2012-12-27 Sequenom, Inc. Methods and processes for non-invasive assessment of a genetic variation
US8712697B2 (en) 2011-09-07 2014-04-29 Ariosa Diagnostics, Inc. Determination of copy number variations using binomial probability calculations
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10196681B2 (en) 2011-10-06 2019-02-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9984198B2 (en) 2011-10-06 2018-05-29 Sequenom, Inc. Reducing sequence read count error in assessment of complex genetic variations
US10424394B2 (en) 2011-10-06 2019-09-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2013052907A2 (en) 2011-10-06 2013-04-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
JP6431769B2 (en) 2012-01-20 2018-11-28 セクエノム， インコーポレイテッド Diagnostic process including experimental conditions as factors
EP3584327A1 (en) 2012-01-27 2019-12-25 The Board of Trustees of the Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
EP4155401A1 (en) 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US10504613B2 (en) 2012-12-20 2019-12-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10289800B2 (en) 2012-05-21 2019-05-14 Ariosa Diagnostics, Inc. Processes for calculating phased fetal genomic sequences
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US10497461B2 (en) 2012-06-22 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2014011928A1 (en) 2012-07-13 2014-01-16 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
WO2014015269A1 (en) 2012-07-19 2014-01-23 Ariosa Diagnostics, Inc. Multiplexed sequential ligation-based detection of genetic variants
US10482994B2 (en) 2012-10-04 2019-11-19 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US20130309666A1 (en) 2013-01-25 2013-11-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
CN103131709B (en) * 2013-02-18 2014-12-17 石河子大学 Ribonucleic acid (RNA) interference fragment of zinc finger-x (zfx) gene and application of RNA interference fragment in mouse sex control
EP2961851B1 (en) 2013-02-28 2018-04-25 The Chinese University Of Hong Kong Maternal plasma transcriptome analysis by massively parallel rna sequencing
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
EP3385717A3 (en) 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
WO2014168711A1 (en) 2013-03-13 2014-10-16 Sequenom, Inc. Primers for dna methylation analysis
EP4187543A1 (en) 2013-04-03 2023-05-31 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
CA2910205C (en) 2013-05-24 2023-04-04 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10622094B2 (en) 2013-06-21 2020-04-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP4136972A1 (en) 2013-07-24 2023-02-22 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
CA2925528C (en) 2013-10-04 2023-09-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
CA2925111C (en) 2013-10-07 2024-01-16 Sequenom, Inc. Methods and processes for non-invasive assessment of chromosome alterations
EP3736344A1 (en) 2014-03-13 2020-11-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US20160034640A1 (en) 2014-07-30 2016-02-04 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
EP3491560A1 (en) 2016-07-27 2019-06-05 Sequenom, Inc. Genetic copy number alteration classifications
EP3491381A1 (en) 2016-07-29 2019-06-05 Streck, Inc. Suspension composition for hematology analysis control
JP7237003B2 (en) 2017-01-24 2023-03-10 セクエノム， インコーポレイテッド Methods and processes for evaluation of gene fragments
WO2020113577A1 (en) * 2018-12-07 2020-06-11 深圳华大生命科学研究院 Method for constructing target gene library, detection device and application thereof
EP3924972A4 (en) 2019-02-14 2023-03-29 Mirvie, Inc. Methods and systems for determining a pregnancy-related state of a subject

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0938320T3 (en) 1996-03-26 2010-10-18 Michael S Kopreski Method of extracting extracellular RNA from plasma or serum to detect, monitor or assess cancer
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis

Also Published As

Publication number Publication date
AU2001295738A1 (en) 2002-04-29
CN1469932A (en) 2004-01-21
CN1219074C (en) 2005-09-14
US6664056B2 (en) 2003-12-16
WO2002033120A2 (en) 2002-04-25
HK1058529A1 (en) 2004-05-21
US20020045176A1 (en) 2002-04-18
WO2002033120A3 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
WO2002033120B1 (en) Non-invasive prenatal monitoring
CA2282793A1 (en) Non-invasive prenatal diagnosis
Honda et al. Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum
CN100379882C (en) Circulating mRNA as diagnostic markers for pregnancy-related disorders
Zhong et al. Fluctuation of maternal and fetal free extracellular circulatory DNA in maternal plasma
US20080108071A1 (en) Methods and Systems to Determine Fetal Sex and Detect Fetal Abnormalities
EP2792751B1 (en) Method and system for determining whether genome is abnormal
CN106191233B (en) Kit for detecting chromosome aneuploidy by multiple real-time quantitative PCR (polymerase chain reaction) and application thereof
Picchiassi et al. The best approach for early prediction of fetal gender by using free fetal DNA from maternal plasma
CN105765076B (en) A kind of chromosomal aneuploidy detection method and device
WO2005047532A1 (en) Improved method of performing genetic analyses on reproductive tract cell samples
Farina et al. Testing normality of fetal DNA concentration in maternal plasma at 10–12 completed weeks' gestation: a preliminary approach to a new marker for genetic screening
Hamada et al. Mid‐trimester fetal sex determination from maternal peripheral blood by fluorescence in situ hybridization without enrichment of fetal cells
Cirigliano et al. Rapid prenatal diagnosis of aneuploidies and zygosity in multiple pregnancies by amniocentesis with single insertion of the needle and quantitative fluorescent PCR
CN111944894B (en) Molecular marker for prenatal noninvasive diagnosis of cleft lip and palate, neural tube malformation and congenital heart disease and application thereof
CN111944893B (en) MiRNA molecular marker related to prenatal noninvasive diagnosis of cleft lip and palate and application thereof
CN112899358A (en) Noninvasive prenatal fetal chromosome aneuploidy detection method and kit thereof
KR20130054492A (en) Method for detecting cell free fetal nucleic acid in plasma of pregnant woman
CN103074416B (en) A kind of method for detecting five numerical abnormalities of chromosomes
Sonek et al. Identification of fetal aneuploidy with dual‐probe fluorescence in situ hybridization analysis in circulating trophoblasts after enrichment using a high‐sensitivity microfluidic platform
Banzola et al. Isolation of serum nucleic acids for fetal DNA analysis: comparison of manual and automated extraction methods
KR101696707B1 (en) Composition for detecing fetal epigenetic markers and detecting method thereof
EP3202912A1 (en) Noninvasive method and system for determining fetal chromosomal aneuploidy
KR101546364B1 (en) Composition for detecing fetal epigenetic markers and detecting method thereof
Mellali et al. Prenatal BoBsTM in the cytogenetic analysis of products of spontaneous miscarriage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 018174450

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP